Welcome to our dedicated page for GSK plc SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025.
The report is available online on both GSK’s annual report website and the SEC’s website. A hard copy of the 2025 Annual Report and the Notice of Annual General Meeting is expected to be available on or about 25 March 2026, and shareholders can request free hard copies of the complete audited financial statements from GSK’s UK registrar or its US ADR depositary.
GSK plc filed its 2025 Form 20-F annual report, highlighting strong growth and major pipeline progress. Sales exceeded £32 billion, up 4% at reported rates and 7% at constant exchange. Total operating profit rose 97%, while core operating profit grew 7% reported and 11% at constant exchange.
Total earnings per share more than doubled, and core EPS increased 8% reported and 12% at constant exchange. Cash generation reached £8.9 billion, supporting a dividend of 66p per share, up from 61p. R&D spending was £7.5 billion, up 18% reported, backing 58 pipeline assets and five key 2025 approvals including Exdensur, Blenrep, Nucala, Blujepa and Penmenvy.
The report details a leadership transition, with Emma Walmsley stepping down as CEO at year-end and former Chief Commercial Officer Luke Miels taking over. Management emphasizes executing launches, advancing late-stage assets in respiratory, oncology, HIV and hepatology, and using AI and business development to drive growth toward and beyond 2031.
GSK plc reports that on 05 March 2026 it repurchased 650,000 ordinary shares at prices between 2,072.00p and 2,135.00p, with a volume‑weighted average price of 2,102.05p. These shares will be held as treasury shares under its existing buyback programme operated via BNP Paribas.
Since 17 February 2026, GSK has bought back 6,466,000 ordinary shares. After this latest transaction, it holds 246,357,094 shares in treasury and has 4,069,805,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 6.05% of voting rights.
GSK plc has published its Annual Report 2025 for the year ended 31 December 2025 on its dedicated website. The report has also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection in accordance with UK listing and transparency rules.
Shareholders who have opted for paper communications will receive hard copies of the Annual Report 2025 and the 2026 Annual General Meeting notice on or around 25 March 2026, with the AGM notice made available to all other shareholders on the same date. GSK describes itself as a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.
GSK plc reports that on 04 March 2026 it repurchased 550,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at prices between 2,109.00p and 2,149.00p per share and a volume‑weighted average of 2,129.91p.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought 5,816,000 ordinary shares. After this transaction, it holds 245,707,094 shares in treasury and has 4,070,455,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.04% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan. The transaction involved 11.569 ADS at a price of $58.6439 per ADS, executed on 2026-03-02 on the New York Stock Exchange.
GSK plc reports that it bought back 630,000 ordinary shares on 3 March 2026 at a volume‑weighted average price of 2,139.22p, with prices ranging from 2,116.00p to 2,169.00p per share. The shares will be held in treasury as part of its existing share buyback programme executed through BNP Paribas under a non‑discretionary agreement announced on 17 February 2026.
Since that date, GSK has repurchased a total of 5,266,000 ordinary shares. After this latest transaction, it holds 245,157,094 ordinary shares in treasury and has 4,071,005,394 ordinary shares in issue, all carrying voting rights. The percentage of voting rights represented by the treasury shares is confirmed at 6.02%, a figure shareholders can use when assessing disclosure thresholds for holdings.
GSK plc has completed its previously announced acquisition of RAPT Therapeutics, valuing RAPT at an approximate aggregate equity value of $2.2 billion, with GSK’s upfront cash investment around $1.9 billion net of cash acquired.
The deal gives GSK global rights to the food-allergy candidate ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong. Ozureprubart is a long-acting anti-IgE monoclonal antibody in phase IIb development, aiming for 12‑week dosing versus current 2–4 week injections and potentially serving patients currently ineligible for existing anti‑IgE therapy.
Phase IIb monotherapy data from the prestIgE trial are expected in 2027, with phase III studies planned in at‑risk adult and paediatric populations. GSK will also assume success‑based milestone and royalty obligations for ozureprubart owed to Shanghai Jeyou Pharmaceutical.
GSK plc reports that on 2 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas, at a volume‑weighted average price of 2,180.14p, with prices ranging between 2,168.00p and 2,195.00p per share.
The shares will be held as treasury stock under GSK’s existing buyback programme. Since 17 February 2026, GSK has bought 4,636,000 ordinary shares. After this purchase, it holds 244,527,094 shares in treasury and has 4,071,635,394 voting shares in issue, with treasury shares representing 6.01% of voting rights.